1. Home
  2. NVT vs GMAB Comparison

NVT vs GMAB Comparison

Compare NVT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nVent Electric plc

NVT

nVent Electric plc

HOLD

Current Price

$117.96

Market Cap

19.6B

Sector

Industrials

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$27.50

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVT
GMAB
Founded
1903
1999
Country
United Kingdom
Denmark
Employees
N/A
3029
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.6B
16.9B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NVT
GMAB
Price
$117.96
$27.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
8
Target Price
$126.60
$39.81
AVG Volume (30 Days)
2.1M
1.4M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
0.71%
N/A
EPS Growth
118.78
N/A
EPS
4.31
N/A
Revenue
$3,893,100,000.00
N/A
Revenue This Year
$18.49
$18.09
Revenue Next Year
$10.88
$14.82
P/E Ratio
$27.41
$1.90
Revenue Growth
29.51
N/A
52 Week Low
$41.71
$17.24
52 Week High
$129.94
$35.43

Technical Indicators

Market Signals
Indicator
NVT
GMAB
Relative Strength Index (RSI) 51.36 52.58
Support Level $104.64 $24.95
Resistance Level $120.43 $33.75
Average True Range (ATR) 5.53 0.57
MACD -0.06 0.33
Stochastic Oscillator 35.67 98.84

Price Performance

Historical Comparison
NVT
GMAB

About NVT nVent Electric plc

NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: